μ-Opioid  ||| S:0 E:9 ||| JJ
receptor  ||| S:9 E:18 ||| NN
activation  ||| S:18 E:29 ||| NNS
and  ||| S:29 E:33 ||| CC
noradrenaline  ||| S:33 E:47 ||| JJ
transport  ||| S:47 E:57 ||| NN
inhibition  ||| S:57 E:68 ||| NN
by  ||| S:68 E:71 ||| IN
tapentadol  ||| S:71 E:82 ||| FW
in  ||| S:82 E:85 ||| FW
rat  ||| S:85 E:89 ||| FW
single  ||| S:89 E:96 ||| FW
locus  ||| S:96 E:102 ||| FW
coeruleus  ||| S:102 E:112 ||| FW
neurons  ||| S:112 E:120 ||| FW
Tapentadol  ||| S:120 E:131 ||| NNP
is  ||| S:131 E:134 ||| VBZ
a  ||| S:134 E:136 ||| DT
novel  ||| S:136 E:142 ||| NN
analgesic  ||| S:142 E:152 ||| NNS
that  ||| S:152 E:157 ||| WDT
combines  ||| S:157 E:166 ||| VBZ
moderate  ||| S:166 E:175 ||| JJ
μ-opioid  ||| S:175 E:184 ||| JJ
receptor  ||| S:184 E:193 ||| NN
agonism  ||| S:193 E:201 ||| NNS
and  ||| S:201 E:205 ||| CC
noradrenaline  ||| S:205 E:219 ||| JJ
reuptake  ||| S:219 E:228 ||| JJ
inhibition  ||| S:228 E:239 ||| NN
in  ||| S:239 E:242 ||| IN
a  ||| S:242 E:244 ||| DT
single  ||| S:244 E:251 ||| JJ
molecule ||| S:251 E:259 ||| NN
.  ||| S:259 E:261 ||| .
Both  ||| S:261 E:266 ||| DT
mechanisms  ||| S:266 E:277 ||| NNS
of  ||| S:277 E:280 ||| IN
action  ||| S:280 E:287 ||| NN
are  ||| S:287 E:291 ||| VBP
involved  ||| S:291 E:300 ||| VBN
in  ||| S:300 E:303 ||| IN
producing  ||| S:303 E:313 ||| VBG
analgesia ||| S:313 E:322 ||| NNS
;  ||| S:322 E:324 ||| :
however ||| S:324 E:331 ||| RB
,  ||| S:331 E:333 ||| ,
the  ||| S:333 E:337 ||| DT
potency  ||| S:337 E:345 ||| NN
and  ||| S:345 E:349 ||| CC
efficacy  ||| S:349 E:358 ||| NN
of  ||| S:358 E:361 ||| IN
tapentadol  ||| S:361 E:372 ||| NN
in  ||| S:372 E:375 ||| IN
individual  ||| S:375 E:386 ||| JJ
neurons  ||| S:386 E:394 ||| NN
has  ||| S:394 E:398 ||| VBZ
not  ||| S:398 E:402 ||| RB
been  ||| S:402 E:407 ||| VBN
characterized ||| S:407 E:420 ||| VBN
.  ||| S:420 E:422 ||| .
Whole-cell  ||| S:422 E:433 ||| JJ
patch-clamp  ||| S:433 E:445 ||| JJ
recordings  ||| S:445 E:456 ||| NNS
of  ||| S:456 E:459 ||| IN
G-protein-coupled  ||| S:459 E:477 ||| JJ
inwardly  ||| S:477 E:486 ||| NNS
rectifying  ||| S:486 E:497 ||| VBG
K ||| S:497 E:498 ||| NNP
( ||| S:498 E:499 ||| -LRB-
+ ||| S:499 E:500 ||| NNP
)  ||| S:500 E:502 ||| -RRB-
( ||| S:502 E:503 ||| -LRB-
KIR  ||| S:503 E:507 ||| NNP
3.x ||| S:507 E:510 ||| NNP
)  ||| S:510 E:512 ||| -RRB-
currents  ||| S:512 E:521 ||| NNS
were  ||| S:521 E:526 ||| VBD
made  ||| S:526 E:531 ||| VBN
from  ||| S:531 E:536 ||| IN
rat  ||| S:536 E:540 ||| FW
locus  ||| S:540 E:546 ||| FW
coeruleus  ||| S:546 E:556 ||| FW
neurons  ||| S:556 E:564 ||| FW
in  ||| S:564 E:567 ||| FW
brain  ||| S:567 E:573 ||| FW
slices  ||| S:573 E:580 ||| FW
to  ||| S:580 E:583 ||| TO
investigate  ||| S:583 E:595 ||| VB
the  ||| S:595 E:599 ||| DT
potency  ||| S:599 E:607 ||| NN
and  ||| S:607 E:611 ||| CC
relative  ||| S:611 E:620 ||| JJ
efficacy  ||| S:620 E:629 ||| NN
of  ||| S:629 E:632 ||| IN
tapentadol  ||| S:632 E:643 ||| NN
and  ||| S:643 E:647 ||| CC
compare  ||| S:647 E:655 ||| VB
its  ||| S:655 E:659 ||| PRP$
intrinsic  ||| S:659 E:669 ||| JJ
activity  ||| S:669 E:678 ||| NN
with  ||| S:678 E:683 ||| IN
other  ||| S:683 E:689 ||| JJ
clinically  ||| S:689 E:700 ||| NNS
used  ||| S:700 E:705 ||| VBN
opioids ||| S:705 E:712 ||| NN
.  ||| S:712 E:714 ||| .
Tapentadol  ||| S:714 E:725 ||| NNP
showed  ||| S:725 E:732 ||| VBD
agonist  ||| S:732 E:740 ||| JJ
activity  ||| S:740 E:749 ||| NN
at  ||| S:749 E:752 ||| IN
μ  ||| S:752 E:754 ||| JJ
receptors  ||| S:754 E:764 ||| NNS
and  ||| S:764 E:768 ||| CC
was  ||| S:768 E:772 ||| VBD
approximately  ||| S:772 E:786 ||| RB
six  ||| S:786 E:790 ||| CD
times  ||| S:790 E:796 ||| NNS
less  ||| S:796 E:801 ||| RBR
potent  ||| S:801 E:808 ||| JJ
than  ||| S:808 E:813 ||| IN
morphine  ||| S:813 E:822 ||| NN
with  ||| S:822 E:827 ||| IN
respect  ||| S:827 E:835 ||| NN
to  ||| S:835 E:838 ||| TO
KIR  ||| S:838 E:842 ||| NNP
3.x  ||| S:842 E:846 ||| NNP
current  ||| S:846 E:854 ||| JJ
modulation ||| S:854 E:864 ||| NN
.  ||| S:864 E:866 ||| .
The  ||| S:866 E:870 ||| DT
intrinsic  ||| S:870 E:880 ||| JJ
activity  ||| S:880 E:889 ||| NN
of  ||| S:889 E:892 ||| IN
tapentadol  ||| S:892 E:903 ||| NN
was  ||| S:903 E:907 ||| VBD
lower  ||| S:907 E:913 ||| JJR
than  ||| S:913 E:918 ||| IN
[ ||| S:918 E:919 ||| -LRB-
Met ||| S:919 E:922 ||| NNP
] ||| S:922 E:923 ||| -RRB-
enkephalin ||| S:923 E:933 ||| NN
,  ||| S:933 E:935 ||| ,
morphine  ||| S:935 E:944 ||| NN
and  ||| S:944 E:948 ||| CC
oxycodone ||| S:948 E:957 ||| NN
,  ||| S:957 E:959 ||| ,
but  ||| S:959 E:963 ||| CC
higher  ||| S:963 E:970 ||| JJR
than  ||| S:970 E:975 ||| IN
buprenorphine  ||| S:975 E:989 ||| NN
and  ||| S:989 E:993 ||| CC
pentazocine ||| S:993 E:1004 ||| NN
.  ||| S:1004 E:1006 ||| .
Tapentadol  ||| S:1006 E:1017 ||| NNP
inhibited  ||| S:1017 E:1027 ||| VBD
the  ||| S:1027 E:1031 ||| DT
noradrenaline  ||| S:1031 E:1045 ||| JJ
transporter  ||| S:1045 E:1057 ||| NN
( ||| S:1057 E:1058 ||| -LRB-
NAT ||| S:1058 E:1061 ||| NNP
)  ||| S:1061 E:1063 ||| -RRB-
with  ||| S:1063 E:1068 ||| IN
potency  ||| S:1068 E:1076 ||| JJ
similar  ||| S:1076 E:1084 ||| JJ
to  ||| S:1084 E:1087 ||| TO
that  ||| S:1087 E:1092 ||| DT
at  ||| S:1092 E:1095 ||| IN
μ  ||| S:1095 E:1097 ||| JJ
receptors ||| S:1097 E:1106 ||| NNS
.  ||| S:1106 E:1108 ||| .
The  ||| S:1108 E:1112 ||| DT
interaction  ||| S:1112 E:1124 ||| NN
between  ||| S:1124 E:1132 ||| IN
these  ||| S:1132 E:1138 ||| DT
two  ||| S:1138 E:1142 ||| CD
mechanisms  ||| S:1142 E:1153 ||| NNS
of  ||| S:1153 E:1156 ||| IN
action  ||| S:1156 E:1163 ||| NN
was  ||| S:1163 E:1167 ||| VBD
additive  ||| S:1167 E:1176 ||| VBN
in  ||| S:1176 E:1179 ||| IN
individual  ||| S:1179 E:1190 ||| JJ
LC  ||| S:1190 E:1193 ||| NNP
neurons ||| S:1193 E:1200 ||| NN
.  ||| S:1200 E:1202 ||| .
Tapentadol  ||| S:1202 E:1213 ||| JJ
displays  ||| S:1213 E:1222 ||| NNS
similar  ||| S:1222 E:1230 ||| JJ
potency  ||| S:1230 E:1238 ||| NN
for  ||| S:1238 E:1242 ||| IN
both  ||| S:1242 E:1247 ||| DT
µ  ||| S:1247 E:1249 ||| JJ
receptor  ||| S:1249 E:1258 ||| NN
activation  ||| S:1258 E:1269 ||| NNS
and  ||| S:1269 E:1273 ||| CC
NAT  ||| S:1273 E:1277 ||| NNP
inhibition  ||| S:1277 E:1288 ||| NN
in  ||| S:1288 E:1291 ||| IN
functioning  ||| S:1291 E:1303 ||| VBG
neurons ||| S:1303 E:1310 ||| NNS
.  ||| S:1310 E:1312 ||| .
The  ||| S:1312 E:1316 ||| DT
intrinsic  ||| S:1316 E:1326 ||| JJ
activity  ||| S:1326 E:1335 ||| NN
of  ||| S:1335 E:1338 ||| IN
tapentadol  ||| S:1338 E:1349 ||| NN
at  ||| S:1349 E:1352 ||| IN
the  ||| S:1352 E:1356 ||| DT
μ  ||| S:1356 E:1358 ||| JJ
receptor  ||| S:1358 E:1367 ||| NN
lies  ||| S:1367 E:1372 ||| VBZ
between  ||| S:1372 E:1380 ||| IN
that  ||| S:1380 E:1385 ||| DT
of  ||| S:1385 E:1388 ||| IN
buprenorphine  ||| S:1388 E:1402 ||| NN
and  ||| S:1402 E:1406 ||| CC
oxycodone ||| S:1406 E:1415 ||| NN
,  ||| S:1415 E:1417 ||| ,
potentially  ||| S:1417 E:1429 ||| RB
explaining  ||| S:1429 E:1440 ||| VBG
the  ||| S:1440 E:1444 ||| DT
favourable  ||| S:1444 E:1455 ||| JJ
profile  ||| S:1455 E:1463 ||| NN
of  ||| S:1463 E:1466 ||| IN
side  ||| S:1466 E:1471 ||| NN
effects ||| S:1471 E:1478 ||| NNS
,  ||| S:1478 E:1480 ||| ,
related  ||| S:1480 E:1488 ||| VBN
to  ||| S:1488 E:1491 ||| TO
μ  ||| S:1491 E:1493 ||| VB
receptors ||| S:1493 E:1502 ||| NNS
.  ||| S:1502 E:1504 ||| .
This  ||| S:1504 E:1509 ||| DT
article  ||| S:1509 E:1517 ||| NN
is  ||| S:1517 E:1520 ||| VBZ
part  ||| S:1520 E:1525 ||| NN
of  ||| S:1525 E:1528 ||| IN
a  ||| S:1528 E:1530 ||| DT
themed  ||| S:1530 E:1537 ||| JJ
section  ||| S:1537 E:1545 ||| NN
on  ||| S:1545 E:1548 ||| IN
Opioids ||| S:1548 E:1555 ||| NNP
:  ||| S:1555 E:1557 ||| :
New  ||| S:1557 E:1561 ||| NNP
Pathways  ||| S:1561 E:1570 ||| NNP
to  ||| S:1570 E:1573 ||| TO
Functional  ||| S:1573 E:1584 ||| NNP
Selectivity ||| S:1584 E:1595 ||| NNP
.  ||| S:1595 E:1597 ||| .
To  ||| S:1597 E:1600 ||| TO
view  ||| S:1600 E:1605 ||| VB
the  ||| S:1605 E:1609 ||| DT
other  ||| S:1609 E:1615 ||| JJ
articles  ||| S:1615 E:1624 ||| NNS
in  ||| S:1624 E:1627 ||| IN
this  ||| S:1627 E:1632 ||| DT
section  ||| S:1632 E:1640 ||| NN
visit  ||| S:1640 E:1646 ||| NN
http ||| S:1646 E:1650 ||| NNS
: ||| S:1650 E:1651 ||| :
-dx.doi.org ||| S:1651 E:1662 ||| CD
/ ||| S:1662 E:1663 ||| CD
10.1111 ||| S:1663 E:1670 ||| CD
/ ||| S:1670 E:1671 ||| CD
bph.2015.172.issue-2 ||| S:1671 E:1691 ||| CD
.  ||| S:1691 E:1693 ||| .
